The lung in paracoccidioidomycosis: new insights into old problems

Carregando...
Imagem de Miniatura
Citações na Scopus
29
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Citação
CLINICS, v.68, n.4, p.441-448, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVES: Chronic paracoccidioidomycosis can diffusely affect the lungs. Even after antifungal therapy, patients may present with residual respiratory abnormalities due to fungus-induced lung fibrosis. METHODS: A cross-sectional analysis of 50 consecutive inactive, chronic paracoccidioidomycosis patients was performed using high resolution computed tomography, pulmonary function tests, ergospirometry, the six-minute walk test and health-related quality of life questionnaires. RESULTS: Radiological abnormalities were present in 98% of cases, the most frequent of which were architectural distortion (90%), reticulate and septal thickening (88%), centrilobular and paraseptal emphysema (84%) and parenchymal bands (74%). Patients typically presented with a mild obstructive disorder and a mild reduction in diffusion capacity with preserved exercise capacity, including VO(2)max and six-minute walking distance. Patient evaluation with the Saint-George Respiratory Questionnaire showed low impairment in the health-related quality of life, and the Medical Research Council questionnaire indicated a low dyspnea index. There were, however, patients with significant oxygen desaturation upon exercise that was associated with respiratory distress compared with the non-desaturated patients. The initial counterimmunoelectrophoresis of these patients was higher and lung emphysema was more prominent; however, there were no differences in the interstitial fibrotic tomographic abnormalities, tobacco exposure, functional responses, exercise capacity or quality of life. CONCLUSIONS: Inactive, chronic paracoccidioidomycosis patients show persistent and disseminated radiological abnormalities by high resolution computed tomography, short impairments in pulmonary function and low impacts on aerobic capacity and quality of life. However, there was a subset of individuals whose functional impairment was more severe. These patients present with higher initial serology and more severe emphysema, stressing the importance of adequate treatment associated with tobacco exposure cessation.
Palavras-chave
Paracoccidioidomycosis, Lung, Pulmonary Function, Quality Of Life, Computed Tomography
Referências
  1. Afonso J E, 1979, Rev Inst Med Trop Sao Paulo, V21, P269
  2. Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111
  3. Barreto MM, 2012, RADIOGRAPHICS, V32, P71, DOI 10.1148/rg.321115052
  4. Bellissimo-Rodrigues F, 2011, AM J TROP MED HYG, V85, P546, DOI 10.4269/ajtmh.2011.11-0084
  5. Benard G, 2008, MYCOPATHOLOGIA, V165, P209, DOI 10.1007/s11046-007-9065-0
  6. Bestall JC, 1999, THORAX, V54, P581
  7. Bethlem E P, 1999, Curr Opin Pulm Med, V5, P319, DOI 10.1097/00063198-199909000-00010
  8. Blotta MHSL, 1999, AM J TROP MED HYG, V61, P390
  9. Calich VLG, 1998, RES IMMUNOL, V149, P407, DOI 10.1016/S0923-2494(98)80764-5
  10. CAMPOS EP, 1986, REV I MED TROP, V28, P330
  11. CAMPOS EP, 1991, REV I MED TROP, V33, P267, DOI 10.1590/S0036-46651991000400005
  12. Coutinho Ziadir Francisco, 2002, Cad Saude Publica, V18, P1441, DOI 10.1590/S0102-311X2002000500037
  13. Del Negro GMB, 2000, J MED MICROBIOL, V49, P37
  14. Ferrer M, 2002, EUR RESPIR J, V19, P405, DOI 10.1183/09031936.02.00213202
  15. Funari M, 1999, AM J ROENTGENOL, V173, P59
  16. Jankowich MD, 2012, CHEST, V141, P222, DOI 10.1378/chest.11-1062
  17. Kim WJ, 2011, EUR RESPIR J, V37, P39, DOI 10.1183/09031936.00173009
  18. Kovelis Demetria, 2008, J Bras Pneumol, V34, P1008, DOI 10.1590/S1806-37132008001200005
  19. LEMLE A, 1983, CHEST, V83, P827, DOI 10.1378/chest.83.5.827
  20. LEMLE A, 1970, AM J MED, V48, P434, DOI 10.1016/0002-9343(70)90042-2
  21. Lemle A, 1983, Rev Inst Med Trop Sao Paulo, V25, P73
  22. Lutz A, 1908, BRAS MED, P121
  23. Marchiori E, 2012, CHEST, V141, P1260, DOI 10.1378/chest.11-1050
  24. Marchiori E, 2009, EUR J RADIOL, V77, P80
  25. Menezes VM, 2006, COCHRANE DB SYST REV
  26. Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
  27. Naranjo TW, 2010, PULM PHARMACOL THER, V24, P81
  28. Neder JA, 1999, BRAZ J MED BIOL RES, V32, P703
  29. Neder JA, 1999, EUR RESPIR J, V14, P1304, DOI 10.1183/09031936.99.14613049
  30. Neder JA, 1999, BRAZ J MED BIOL RES, V32, P729, DOI 10.1590/S0100-879X1999000600008
  31. Pereira Carlos Alberto de Castro, 2007, J Bras Pneumol, V33, P397, DOI 10.1590/S1806-37132007000400008
  32. de Camargo ZP, 2008, MYCOPATHOLOGIA, V165, P289, DOI 10.1007/s11046-007-9060-5
  33. Poulain M, 2003, CHEST, V123, P1401, DOI 10.1378/chest.123.5.1401
  34. Queiroz-Telles F, 2011, SEMIN RESP CRIT CARE, V32, P764, DOI 10.1055/s-0031-1295724
  35. RESTREPO S, 1992, J MED VET MYCOL, V30, P173
  36. Rodrigues GD, 2010, J BRAS PNEUMOL, V36, P356, DOI 10.1590/S1806-37132010000300014
  37. Santos WA, 2003, CAD SAUDE PUBLICA, V19, P245, DOI 10.1590/S0102-311X2003000100027
  38. Shikanai-Yasuda MA, 2002, MED MYCOL, V40, P411, DOI 10.1080/714031125
  39. Shikanai-Yasuda MA, 2006, REV SOC BRAS MED TRO, V39, P297, DOI 10.1590/S0037-86822006000300017
  40. Soares MR, 2011, J BRAS PNEUMOL, V37, P576, DOI 10.1590/S1806-37132011000500003
  41. Sousa TC, 2000, J PNEUMOLOGIA, V16, P119
  42. Souza AS, 2006, AM J ROENTGENOL, V187, P1248, DOI 10.2214/AJR.05.1065
  43. STAMM AM, 1983, CHEST, V83, P911, DOI 10.1378/chest.83.6.911
  44. TERCARIOLI GR, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-92
  45. Tobon AM, 2003, CLIN INFECT DIS, V37, P898, DOI 10.1086/377538
  46. TUDER RM, 1985, MYCOPATHOLOGIA, V92, P179, DOI 10.1007/BF00437631